Savolitinib + osimertinib treatment in ChinaAfter resistance to targeted therapy, find a path forward.
When disease progresses after EGFR-targeted therapy and MET amplification is detected, savolitinib plus osimertinib in China offers eligible patients a treatment pathway directed at the resistance mechanism. Shanghai specialists involved in pivotal research can consider new test results alongside your full medication history when planning the next step.
Free initial service consultation · Understand your options and budget before you travel
Seeking disease control after resistance · SACHI
Savolitinib + osimertinib · Median PFS
8.2 months
Platinum-based chemotherapy · Median PFS
4.5 months
Investigator-assessed results for all randomised patients; limited to the study population with EGFR-mutated disease and MET amplification progressing after EGFR-TKI treatment. Figures from different subgroups and assessment methods cannot be mixed; they are not an individual's expected outcome or overall survival. View the evidence
8.2 versus 4.5 months is investigator-assessed median PFS in all randomised SACHI patients, not an individual prediction or overall survival. ¥5,289.90 is only a historical 2024 price for one box of savolitinib, not a monthly combination cost or complete quote. View sources
Identify the resistance target and plan treatment ahead
When MET amplification contributes to EGFR-targeted treatment resistance, blocking both EGFR and MET offers a mechanism-directed pathway. A specific regimen is available in China, and research involving Shanghai Chest Hospital specialists directly addresses this patient group.
A mechanism-matched targeted option after resistance
In June 2025, China approved savolitinib combined with osimertinib for eligible patients with advanced nonsquamous non-small cell lung cancer. Requirements include progression after prior EGFR-TKI treatment and MET amplification; it does not apply to every form of targeted treatment resistance.
Seek to delay the next disease progression
Among all randomised SACHI patients, investigator-assessed median PFS was 8.2 months with combined targeted therapy versus 4.5 months with platinum-based chemotherapy. Study results do not predict individual response; chemotherapy and other options still need discussion.
Find Shanghai specialists experienced in resistance research
Lu Shun of Shanghai Chest Hospital and Wang Jie were co-principal investigators of SACHI. Specialist assessment can connect the original EGFR results, MET testing after resistance, the generation of previous targeted drugs and imaging evidence of progression.
Dual targeted treatment involves paying for both savolitinib and osimertinib. Seek prices for both drugs, testing and follow-up on a fully self-funded basis for foreign patients without Chinese health insurance or free-drug assistance. The available historical single-box savolitinib price is for reference only.
Historical price for one box of savolitinib
RMB ¥5,289.90 per box; 200mg × 21 tablets, published by Suzhou Kowloon Hospital in 2024-06
Date limitations of the price
This published price predates approval of the combination indication in June 2025 and does not represent current combination treatment prices.
The second medicine
Osimertinib is charged separately; the hospital must confirm actual doses, strengths and current prices for both drugs.
Testing and ongoing treatment
Resistance testing, any additional biopsy needed, tests, follow-up and management of side effects are additional.
Costs associated with travel to China
Confirm medical and coordination services, interpreting, transport and accommodation as separate items.
No current personal or international patient quote is available for the combination. One box of savolitinib cannot be treated as the monthly or full-course cost of the combination, or used to promise a cost advantage. Confirm current drug supply, international patient acceptance and the start date with the treating hospital.
Finding treatment that fits you starts with the reports you already have.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
Original diagnosisEGFR mutation-positive locally advanced or metastatic nonsquamous non-small cell lung cancer.
Previous treatmentDisease progression after EGFR-TKI treatment; list the drugs, treatment dates, dose adjustments and sites of progression.
Resistance mechanismMET amplification detected; a doctor must review the testing method, threshold and sample timing, and assess its relationship to resistance.
Avoid confusing different findingsMET amplification is not MET exon 14 skipping. MET protein expression, gene amplification, exon 14 skipping and fusion are not interchangeable; a separate savolitinib monotherapy indication cannot be directly applied here.
Overall assessmentConsider performance status, comorbidities, previous drug reactions and other options when deciding on the combination; do not combine medicines or change prescriptions yourself.
Which treatment comparison informs disease control after resistance?
SACHI compared savolitinib + osimertinib with platinum-based chemotherapy in lung cancer with EGFR mutations and MET amplification progressing after EGFR-TKI treatment. The figures below use investigator assessments for all randomised patients.
Median progression-free survival (PFS)
8.2 months for combined targeted therapy versus 4.5 months for platinum-based chemotherapy; investigator assessment of all randomised patients.
Study and applicability
A phase III randomised comparison; different prior-treatment subgroups and assessment methods may yield different figures. Subgroup outcomes cannot be treated as everyone's expected result.
Treatment pathway in China
The combination use for eligible advanced nonsquamous non-small cell lung cancer was approved in June 2025; this page cites the original study disclosure dated 2026-01-14.
Other regions
Switzerland granted temporary approval for the related combination use in 2026, so it is not exclusive to China.
Median PFS is not overall survival or a promise of individual efficacy. MET amplification requires confirmation under specific testing criteria; the study does not mean every patient with resistance is suited to dual targeted treatment, and other indications cannot be directly substituted.
In Shanghai, let specialist experience help inform your next step.
Explore Shanghai teams whose research and clinical focus relate to your condition and may warrant further discussion.
Lu Shun
Lung cancer specialist · Co-principal investigator of SACHI
Shanghai Chest Hospital, affiliated with Shanghai Jiao Tong University School of Medicine
Lu Shun of Shanghai Chest Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and Wang Jie were co-principal investigators of SACHI, which directly focused on patients progressing after EGFR-targeted treatment with MET amplification. The team's lung cancer resistance research experience may inform specialist assessment, bringing together original EGFR results, post-resistance MET testing, prior drug generations and imaging progression before discussing combined targeted therapy, chemotherapy and other choices. Research experience does not confirm a partnership, drug supply or an appointment; the hospital must confirm the treating team, prescription, schedule and international patient charges.
Published research and clinical information can inform hospital selection; specific doctors, drug availability, international clinic charges and appointment dates are subject to confirmation by the hospital.
You do not need to book flights first. Clarify treatment and costs before you travel.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
Bring the original pathology and complete EGFR report to establish the initial subtype.
Submit the complete post-resistance MET report, including method, threshold, sample type and collection date.
List all targeted medicines, dose adjustments, treatment durations and progression records chronologically to support a full resistance assessment.
Prepare the two most recent imaging studies and information on progression sites, plus comorbidities and previous adverse effects.
Before departure, confirm the hospital assessment, any additional tests, and itemised medical and coordination service budgets. Then arrange flights, accommodation, interpreting, follow-up after returning home, medication supply and emergency contacts. You do not need to arrange new tests yourself for an initial consultation.
Start the first conversation with the records you already have.
You do not need to arrange new tests yourself for an initial consultation.
Get answers to the questions that matter to you before you travel.
Costs, potential benefit and further treatment deserve specific answers before departure.
Can I simply add savolitinib after osimertinib resistance?
No. Disease progression and the resistance mechanism must be confirmed, including whether MET amplification meets the regimen's criteria. The prescription also depends on performance status, comorbidities and alternatives. Do not combine drugs or adjust doses yourself.
Does “MET-positive” on my report mean MET amplification here?
Not necessarily. Protein expression, gene amplification, exon 14 skipping and fusion are different findings. The full report's method, threshold and sample timing are needed; “MET-positive” alone is not a basis for adding a drug. A savolitinib monotherapy indication also cannot be directly applied.
Can 8.2 months predict my outcome?
No. It is investigator-assessed median PFS for the combined targeted therapy group among all randomised SACHI patients, versus 4.5 months with platinum-based chemotherapy; it is not overall survival. Results for prior-treatment subgroups and different assessment methods cannot be mixed and do not represent an individual's expected outcome.
How much does a month of combination treatment cost?
There is no current complete quote. ¥5,289.90 is a historical published 2024 price for one box of savolitinib 200mg × 21 tablets, predating combination approval. Osimertinib, tests, follow-up and other costs must also be included. Do not extrapolate a monthly combination cost from this amount; request fully self-funded prices based on the actual doses and strengths of both medicines.
Must I repeat a biopsy or testing before consulting?
You do not need to arrange new tests yourself for an initial service consultation. Original and post-resistance samples, and tissue and blood tests, may give different results. The doctor first assesses whether existing information explains resistance, then decides whether further biopsy or testing is needed.
Which risks need attention with the combination?
Monitor for oedema, gastrointestinal effects, abnormal liver function and serious adverse effects such as pneumonitis. The monitoring plan should reflect existing disease, previous drug reactions and use of the two medicines together.
Is this combination available only in China?
No. The related combination use also received temporary approval in Switzerland in 2026. China's specific value is an established targeted treatment pathway and relevant clinical research experience; current supply, patient acceptance and scheduling still require hospital confirmation.
Turn an understanding of resistance into your next treatment plan.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
